DermTech: Carcinome Clinical Study Enrollment Complete

May 28, 2018

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced completion of enrollment in the Carcinome™ clinical study. The goal of the Carcinome™ study is to develop a non-invasive genomic test to differentiate basal cell carcinoma (BCC) and squamous cell carcinoma (SCC) from non-cancerous lesions like actinic keratosis. More than 600 patients were enrolled in this study.

Over 4 million cases of BCC and 1 million cases of SCC are diagnosed each year in the US, with more than 13 million surgical biopsies performed to diagnose these non-melanoma skin cancers. Carcinome™ is the third non-invasive skin cancer test being developed by DermTech using their proprietary molecular pathology platform technology.

“We are excited to complete this phase of the study and look forward to Carcinome’s™ full validation to successfully distinguish BCC and SCC from non-cancerous lesions, all with skin tissue collected non-invasively using adhesive patches,” said Zuxu Yao, PhD, DermTech’s Chief Scientific Officer and head of Research and Development.

Facebook Comments

Register

We’re glad to see you’re enjoying PracticalDermatology…
but how about a more personalized experience?

Register for free